Managing weight loss with telotristat ethyl in patients with metastatic pancreatic ductal adenocarcinoma may improve survival ...

This symposium promises to be an enlightening experience for all attendees, providing valuable insights into the future of drug development and dissolution science. The topics presented includes ...

Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its first-in-class cancer treatment approach. The company is developing novel treatments ...

United Kingdom, 15 th January 2025: Oxford Drug Design, the Oxford-based AI drug discovery company, has today announced additional in vivo validation for its first-in-class approach against cancer as ...

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...

This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

Harry Sumnall receives funding from public grant awarding bodies for alcohol and other drugs research, and fees from (international) not-for-profit organisations and government departments for ...

Upon abstract acceptance, all posters must be uploaded and recorded on VoiceThread by Jan 31, 2025 All posters that are narrated on VoiceThread by the deadline will be officially listed in the ...

This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

Gradually Moll became addicted to fentanyl. “Slowly, my drug dealers started integrating fentanyl into their supply and though it was more expensive, I needed less of it to get loaded.

Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...